After trading in the $30s, Organon & Co. shares fell to $28 in August as I picked up coverage again.

Source: https://seekingalpha.com/article/4589945-organon-a-bitter-pill?source=feed_all_articles

As a group, equities research analysts forecast that Organon & Co. will post 4.23 earnings per share for the current year.

Source: https://www.etfdailynews.com/2023/08/20/hartford-investment-management-co-boosts-stock-position-in-organon-co-nyseogn/

California State Teachers Retirement System’s holdings in Organon & Co. were worth $7,844,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Source: https://www.etfdailynews.com/2023/08/19/california-state-teachers-retirement-system-cuts-stake-in-organon-co-nyseogn/

Equities analysts anticipate that Organon & Co. will post 4.22 earnings per share for the current fiscal year.

Source: https://www.etfdailynews.com/2023/05/22/cibc-world-markets-corp-makes-new-835000-investment-in-organon-co-nyseogn/

Makers of pseudoephedrine-containing drugs include Reckitt Benckiser, McNeil Products Ltd and Organon & Co.

Source: https://www.insurancejournal.com/news/international/2023/02/13/707633.htm

Mirova acquired a new stake in Organon & Co. in the first quarter worth $30,000.

Source: https://www.dailypolitical.com/2023/12/02/sei-investments-co-purchases-33252-shares-of-organon-co-nyseogn.html

Raymond James & Associates owned approximately 0.12% of Organon & Co. worth $6,987,000 as of its most recent filing with the SEC.

Source: https://www.etfdailynews.com/2023/01/14/raymond-james-associates-has-6-99-million-holdings-in-organon-co-nyseogn/

Scissortail Wealth Management LLC bought a new position in Organon & Co. during the 1st quarter valued at approximately $3,279,567,000.

Source: https://www.dailypolitical.com/2023/09/17/cva-family-office-llc-purchases-1020-shares-of-organon-co-nyseogn.html